Literature DB >> 10764326

Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis.

M S Carraway1, A J Ghio, J D Carter, C A Piantadosi.   

Abstract

Pulmonary alveolar proteinosis (PAP) is an idiopathic lung disease in which the alveolar spaces are filled with surfactant. Recently, it has been proposed that PAP is caused by deficiency of granulocyte-macrophage colony-stimulating factor (GM-CSF) because GM-CSF-knockout mice develop the disease. To examine this possibility, we tested the two hypotheses that lung GM-CSF levels are low and that alveolar macrophages (AM) do not respond to GM-CSF in patients with PAP. Data from 10 adult patients with PAP who underwent therapeutic whole-lung lavage were compared with those of 10 healthy volunteers who underwent bronchoalveolar lavage (BAL) by fiberoptic bronchoscopy. Bronchoalveolar lavage fluid (BALF) and plasma were collected and analyzed for total protein and levels of GM-CSF, interleukin-3, and tumor necrosis factor (TNF)-alpha. Isolated AM were cultured with or without lipopolysaccharide (LPS) or GM-CSF, and production of GM-CSF and TNF-alpha was measured after 24 h. GM-CSF in BALF and plasma was higher in PAP than in control subjects (p </= 0.05), and was detectable under both reducing and nonreducing conditions as a 28-kD protein in BALF from the PAP patients. GM-CSF release by unstimulated AM from PAP patients was higher than in cells from control subjects, but the responses to LPS were similar. Mean TNF-alpha release by AM in response to GM-CSF was higher in control subjects than in PAP patients due to a low response in three patients. In conclusion, unbound immunoreactive GM-CSF is detectable in BALF and plasma of PAP patients. Most PAP patients also had intact AM responses to GM-CSF, although some may have had defects in GM-CSF receptor or signal-transduction mechanisms. Although these data exclude lack of GM-CSF production as a common etiology of human PAP, defects in GM-CSF function in PAP are under investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764326     DOI: 10.1164/ajrccm.161.4.9906080

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  14 in total

1.  An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Authors:  M S Kavuru; A Malur; I Marshall; B P Barna; M Meziane; I Huizar; H Dalrymple; R Karnekar; M J Thomassen
Journal:  Eur Respir J       Date:  2011-04-08       Impact factor: 16.671

Review 2.  An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.

Authors:  Paul O Nkadi; T Allen Merritt; De-Ann M Pillers
Journal:  Mol Genet Metab       Date:  2009-02-04       Impact factor: 4.797

3.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

Authors:  Yoshikazu Inoue; Bruce C Trapnell; Ryushi Tazawa; Toru Arai; Toshinori Takada; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masaaki Hojo; Toshio Ichiwata; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Kazunori Oishi; Yoshiko Tsuchihashi; Chinatsu Kaneko; Toshihiro Nukiwa; Mitsunori Sakatani; Jeffrey P Krischer; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

4.  [Classification of pulmonary alveolar proteinosis in newborns, infants, and children].

Authors:  F Brasch; K-M Müller
Journal:  Pathologe       Date:  2004-07       Impact factor: 1.011

5.  Clinical features and outcomes of idiopathic pulmonary alveolar proteinosis in Korean population.

Authors:  Min Kwang Byun; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Jae Jeong Shim; Seung Ick Cha; Soo-Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Moo Suk Park
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

6.  Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects.

Authors:  Kanji Uchida; Koh Nakata; Takuji Suzuki; Maurizio Luisetti; Masato Watanabe; Diana E Koch; Carrie A Stevens; David C Beck; Lee A Denson; Brenna C Carey; Naoto Keicho; Jeffrey P Krischer; Yoshitsugu Yamada; Bruce C Trapnell
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

7.  Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis.

Authors:  F-C Lin; G-D Chang; M-S Chern; Y-C Chen; S-C Chang
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

8.  Cutting Edge: The RNA-Binding Protein Ewing Sarcoma Is a Novel Modulator of Lymphotoxin β Receptor Signaling.

Authors:  Richard Virgen-Slane; Ricardo G Correa; Parham Ramezani-Rad; Seth Steen-Fuentes; Thiago Detanico; Michael J DiCandido; Jun Li; Carl F Ware
Journal:  J Immunol       Date:  2020-01-22       Impact factor: 5.422

9.  Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis.

Authors:  Anagha Malur; Mani S Kavuru; Irene Marshall; Barbara P Barna; Isham Huizar; Reema Karnekar; Mary Jane Thomassen
Journal:  Respir Res       Date:  2012-06-14

10.  Whole lung lavage for pulmonary alveolar proteinosis after surgery for spontaneous pneumothorax.

Authors:  R Stoica; A Macri; I Cordoş; C Bolca
Journal:  J Med Life       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.